AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Treatment for Diabetic Cardiomyopathy

Detailed Technology Description
Heart disease is the lead cause of mortality among diabetic patients in the U.S. UC San Diego researchers have developed a method to treat diabetic cardiomyopathy by gene therapy using an enzyme specific for the removal of a single sugar molecule from proteins such as transcription factors. The researchers demonstrated that elevated extra-cellular glucose levels result in impaired calcium cycling in myocytes, leading to impaired cardiac contractility and poor myocardial performance, by a mechanism involving O-linked glycosylation of nuclear proteins. They found that these effects can be reversed by gene therapy with an enzyme, O-GlcNAcase, which can remove specific O-linked hexosamines from proteins. Delivery of viral vectors encoding O-GlcNAcase to myocytes from diabetic rats markedly improved calcium flux and contractile function.
Supplementary Information
Patent Number: US7919475B2
Application Number: US2006574232A
Inventor: Dillmann, Wolfgang | Clark, Raymond
Priority Date: 25 Aug 2004
Priority Number: US7919475B2
Application Date: 30 Jan 2008
Publication Date: 5 Apr 2011
IPC Current: A61K004800 | A01N006300 | C07H002102 | C07H002104
US Class: 514044R | 42409321 | 435325 | 5360231 | 5360232
Assignee Applicant: The Regents of the University of California
Title: Compositions and methods for improving heart function
Usefulness: Compositions and methods for improving heart function
Summary: The pharmaceutical composition is useful for treating, ameliorating or preventing heart disease comprising poor myocardial performance associated with diabetic cardiomyopathy.
Novelty: New pharmaceutical composition comprising an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid or protein or a compound that increases O-GlcNAc (OGT) transcription or activity, useful in treating heart disease
Industry
Biomedical
Sub Category
Medical Composition
Application No.
7919475
Others

Additional Technologies by these Inventors


Tech ID/UC Case

19673/2004-071-0


Related Cases

2004-071-0

*Abstract
None
*IP Issue Date
Apr 5, 2011
*Principal Investigator

Name: Darrell Belke

Department:


Name: Raymond Clark

Department:


Name: Wolfgang Dillmann

Department:


Name: Gerald Hart

Department:


Name: Ying Hu

Department:

Country/Region
USA

For more information, please click Here
Mobile Device